Quick Answer
ArriVent BioPharma, Inc. reported Total Assets of $333.17 million for fiscal year 2025.
ArriVent BioPharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $333.17M | +21.2% |
| 2024 | $274.94M | +68.6% |
| 2023 | $163.10M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $326.56M | +11.6% | +21.2% |
| June 30, 2025 | $269.51M | -12.7% | +25.1% |
| March 31, 2025 | $215.50M | -34.3% | -21.6% |
| December 31, 2024 | $274.94M | +68.6% | -6.1% |
| September 30, 2024 | $292.71M | — | -5.2% |
| June 30, 2024 | $308.86M | — | -5.8% |
| March 31, 2024 | $327.84M | — | +101.0% |
| December 31, 2023 | $163.10M | — | — |
- ArriVent BioPharma, Inc. showed an increase of +21.2% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s total assets has grown by 104.3% (from $163.10 million to $333.17 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: